In Europe, Centralized OTC Switch Still Has A Few Bugs
This article was originally published in The Tan Sheet
Executive Summary
The European Union's diversity means that when it comes to the new centralized procedure for Rx-to-OTC switches, there are several details yet to be ironed out, according to OTC industry executives
You may also be interested in...
Novartis To Launch Nycomed's PPI Pantoloc Control In 14 European Countries
Novartis will launch the OTC proton pump inhibitor Pantoloc Control (pantoprazole 20 mg) in 14 European countries in the second quarter of 2010 under a co-marketing agreement with the product's originator Nycomed
Novartis To Launch Nycomed's PPI Pantoloc Control In 14 European Countries
Novartis will launch the OTC proton pump inhibitor Pantoloc Control (pantoprazole 20 mg) in 14 European countries in the second quarter of 2010 under a co-marketing agreement with the product's originator Nycomed
Novartis To Launch Nycomed's PPI Pantoloc Control In 14 European Countries
Novartis will launch the OTC proton pump inhibitor Pantoloc Control (pantoprazole 20 mg) in 14 European countries in the second quarter of 2010 under a co-marketing agreement with the product's originator Nycomed